Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Clinton F Stewart

Showing results (141-150 of 220) with videos related to

Pageof 22
Sort By:
Archives of Ophthalmology (Chicago, Ill. : 1960)|November 16, 2011
Real-time ophthalmoscopic findings of superselective intraophthalmic artery chemotherapy in a nonhuman primate modelMatthew W Wilson, John S Jackson, Blanca X Phillips, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2004
Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumorClinton F Stewart, Lisa C Iacono, Murali Chintagumpala, et al.
Pediatric Nephrology (Berlin, Germany)|June 3, 2017
Derivation of new equations to estimate glomerular filtration rate in pediatric oncology patientsVanessa E Millisor, Jessica K Roberts, Yilun Sun, et al.
Cancer Chemotherapy and Pharmacology|October 25, 2014
Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collectionsKaren D Wright, John C Panetta, Arzu Onar-Thomas, et al.
Molecular and Cellular Biology|August 18, 2004
Mrp4 confers resistance to topotecan and protects the brain from chemotherapyMarkos Leggas, Masashi Adachi, George L Scheffer, et al.
Journal of Neuro-Oncology|July 10, 2013
A molecular biology and phase II trial of lapatinib in children with refractory CNS malignancies: a pediatric brain tumor consortium studyMaryam Fouladi, Clinton F Stewart, Susan M Blaney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2007
UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecanClinton F Stewart, John C Panetta, Melinda A O'Shaughnessy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 15, 2010
Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018Katherine E Warren, Stewart Goldman, Ian F Pollack, et al.
Cancer Research|October 20, 2004
Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in miceClinton F Stewart, Markos Leggas, John D Schuetz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2013
Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium studyAmar Gajjar, Clinton F Stewart, David W Ellison, et al.
Pageof 22

Showing results (141-150 of 220) with videos related to

Sort By:
Pageof 22
Archives of Ophthalmology (Chicago, Ill. : 1960)|November 16, 2011
Real-time ophthalmoscopic findings of superselective intraophthalmic artery chemotherapy in a nonhuman primate modelMatthew W Wilson, John S Jackson, Blanca X Phillips, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2004
Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumorClinton F Stewart, Lisa C Iacono, Murali Chintagumpala, et al.
Pediatric Nephrology (Berlin, Germany)|June 3, 2017
Derivation of new equations to estimate glomerular filtration rate in pediatric oncology patientsVanessa E Millisor, Jessica K Roberts, Yilun Sun, et al.
Cancer Chemotherapy and Pharmacology|October 25, 2014
Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collectionsKaren D Wright, John C Panetta, Arzu Onar-Thomas, et al.
Molecular and Cellular Biology|August 18, 2004
Mrp4 confers resistance to topotecan and protects the brain from chemotherapyMarkos Leggas, Masashi Adachi, George L Scheffer, et al.
Journal of Neuro-Oncology|July 10, 2013
A molecular biology and phase II trial of lapatinib in children with refractory CNS malignancies: a pediatric brain tumor consortium studyMaryam Fouladi, Clinton F Stewart, Susan M Blaney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2007
UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecanClinton F Stewart, John C Panetta, Melinda A O'Shaughnessy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 15, 2010
Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018Katherine E Warren, Stewart Goldman, Ian F Pollack, et al.
Cancer Research|October 20, 2004
Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in miceClinton F Stewart, Markos Leggas, John D Schuetz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2013
Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium studyAmar Gajjar, Clinton F Stewart, David W Ellison, et al.
Pageof 22